Valeant Pharmaceuticals International, Inc. (VRX) Position Boosted by Moors & Cabot Inc.

Moors & Cabot Inc. lifted its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 32.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 15,275 shares of the specialty pharmaceutical company’s stock after buying an additional 3,725 shares during the period. Moors & Cabot Inc.’s holdings in Valeant Pharmaceuticals International were worth $267,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Harbor Advisors LLC acquired a new position in Valeant Pharmaceuticals International during the first quarter worth approximately $110,000. NEXT Financial Group Inc increased its position in Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after purchasing an additional 600 shares during the last quarter. Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 10.5% during the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $183,000 after purchasing an additional 1,000 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the last quarter. Finally, IPG Investment Advisors LLC acquired a new position in Valeant Pharmaceuticals International during the second quarter worth approximately $203,000. 50.48% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Position Boosted by Moors & Cabot Inc.” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/10/13/valeant-pharmaceuticals-international-inc-vrx-position-boosted-by-moors-cabot-inc.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 3.1041% on Friday, hitting $13.4007. 2,158,613 shares of the stock were exchanged. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $24.30. The company’s 50 day moving average is $14.00 and its 200 day moving average is $13.52. The stock’s market cap is $4.67 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. Valeant Pharmaceuticals International’s revenue was down 7.7% compared to the same quarter last year. On average, equities research analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current year.

Several equities analysts recently commented on the stock. Guggenheim assumed coverage on shares of Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They set a “buy” rating and a $18.00 price target for the company. Mizuho reaffirmed an “underperform” rating and set a $8.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 20th. Zacks Investment Research lowered shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Thursday. Vetr lowered shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “hold” rating and set a $14.26 price objective for the company. in a research report on Friday. Finally, Canaccord Genuity set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday, August 10th. Five investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.71.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply